Literature DB >> 18404411

'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature.

M Biegstraaten1, I N van Schaik, J M F G Aerts, C E M Hollak.   

Abstract

Gaucher disease is a lysosomal storage disorder, which is classically divided into three types. Type I Gaucher disease is differentiated from types II and III disease by the absence of nervous system involvement. However, an increasing number of reports has emerged on neurological manifestations in patients with type I Gaucher disease. Whether a strict division in three different phenotypes is still valid has been the subject of debate. The main objective of this study was to provide scientific arguments whether a distinction between type I (non-neuronopathic) and types II and III (neuronopathic) Gaucher disease should be maintained. We investigated retrospectively a large Dutch cohort of type I Gaucher disease patients for the prevalence of neurological manifestations and provide an overview of the literature on this topic. A diagnosis of a neurological disease was made 34 times in 75 patients. Forty-five patients reported at least one neurological symptom during the median follow-up time of 11 years. The literature search revealed 86 studies in which type I Gaucher disease patients or carriers of a glucocerebrosidase mutation were described with a neurological disease or a condition which is known to be associated with neurological disease. In conclusion, the term non-neuronopathic Gaucher disease does not seem to be an appropriate characterization of type I Gaucher disease. However, the neurological signs and symptoms in type I Gaucher disease are of a totally different kind from and, in the majority of cases, of much less severity than the signs and symptoms associated with types II and III disease Therefore, type I disease should be classified as a separate phenotype.

Entities:  

Mesh:

Year:  2008        PMID: 18404411     DOI: 10.1007/s10545-008-0832-y

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.750


  112 in total

1.  Iliopsoas hematoma in a young patient with type I Gaucher disease.

Authors:  Marina Jmoudiak; Menachem Itzchaki; Irith Hadas-Halpern; Martin Hrebicek; Katerina Hodanova; Deborah Elstein; Ari Zimran
Journal:  Isr Med Assoc J       Date:  2003-09       Impact factor: 0.892

Review 2.  Neurological manifestations in lysosomal storage disorders - from pathology to first therapeutic possibilities.

Authors:  B Hoffmann; E Mayatepek
Journal:  Neuropediatrics       Date:  2005-10       Impact factor: 1.947

Review 3.  Systemic AL amyloidosis in Gaucher disease. A case report and review of the literature.

Authors:  A Kaloterakis; A Filiotou; J Koskinas; I Raptis; C Zouboulis; H Michelakakis; S Hadziyannis
Journal:  J Intern Med       Date:  1999-12       Impact factor: 8.989

4.  Gaucher's disease: neurologic disorder in adult siblings.

Authors:  J D Miller; R McCluer; J N Kanfer
Journal:  Ann Intern Med       Date:  1973-06       Impact factor: 25.391

5.  Increased operative bleeding during orthopaedic surgery in patients with type I Gaucher disease and bone involvement.

Authors:  K Katz; H Tamary; J Lahav; M Soudry; I J Cohen
Journal:  Bull Hosp Jt Dis       Date:  1999

6.  Cauda equina syndrome due to an intra-dural sacral cyst in type-1 Gaucher disease.

Authors:  Abderrahmane Hamlat; Stephan Saikali; Mohamed Lakehal; Michèle Pommereuil; Xavier Morandi
Journal:  Eur Spine J       Date:  2003-12-20       Impact factor: 3.134

7.  Phenotypic continuum in neuronopathic Gaucher disease: an intermediate phenotype between type 2 and type 3.

Authors:  Ozlem Goker-Alpan; Raphael Schiffmann; Joseph K Park; Barbara K Stubblefield; Nahid Tayebi; Ellen Sidransky
Journal:  J Pediatr       Date:  2003-08       Impact factor: 4.406

8.  ["Spontaneous" hematoma of the psoas in Gaucher's disease].

Authors:  R M Flipo; C Adenis-Lavignasse; B Cortet; P Chastanet; J Goudemand; B Duquesnoy
Journal:  Rev Med Interne       Date:  1992 Jul-Aug       Impact factor: 0.728

9.  Neuropathology provides clues to the pathophysiology of Gaucher disease.

Authors:  Kondi Wong; Ellen Sidransky; Ajay Verma; Tonghui Mixon; Glenn D Sandberg; Laura K Wakefield; Alan Morrison; Alicia Lwin; Carlos Colegial; John M Allman; Raphael Schiffmann
Journal:  Mol Genet Metab       Date:  2004-07       Impact factor: 4.797

10.  Gaucher's disease and glioblastoma multiforme in two siblings: a clinicopathologic study.

Authors:  J C Lyons; B W Scheithauer; W W Ginsburg
Journal:  J Neuropathol Exp Neurol       Date:  1982-01       Impact factor: 3.685

View more
  23 in total

1.  The neurological manifestations of Gaucher disease type 1: the French Observatoire on Gaucher disease (FROG).

Authors:  P Chérin; C Rose; C de Roux-Serratrice; D Tardy; D Dobbelaere; B Grosbois; E Hachulla; R Jaussaud; R-M Javier; E Noël; P Clerson; A Hartmann
Journal:  J Inherit Metab Dis       Date:  2010-06-02       Impact factor: 4.982

2.  Effects of switching from a reduced dose imiglucerase to velaglucerase in type 1 Gaucher disease: clinical and biochemical outcomes.

Authors:  Laura van Dussen; Timothy M Cox; Erik J Hendriks; Elizabeth Morris; Erik M Akkerman; Mario Maas; Johanna E M Groener; Johannes M F G Aerts; Patrick B Deegan; Carla E M Hollak
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

Review 3.  Neuropathic Gaucher disease.

Authors:  Gregory M Pastores
Journal:  Wien Med Wochenschr       Date:  2010-12

4.  Gaucher disease in North Macedonia: Unexpected prevalence of the N370S GBA1 allele with attenuated disease expression.

Authors:  Nevenka Ridova; Sanja Trajkova; Biljana Chonevska; Zlate Stojanoski; Martin Ivanovski; Marija Popova-Labachevska; Simona Stojanovska-Jakimovska; Venko Filipche; Aspazija Sofijanova; Irina Panovska-Stavridis
Journal:  Mol Genet Metab Rep       Date:  2022-07-08

5.  Healthcare resource utilization and cost of care for Gaucher patients in Iran.

Authors:  Majid Davari; Azita Nabizadeh; Maliheh Kadivar; Akbar Abdollahi Asl; Peymaneh Sarkheil
Journal:  J Diabetes Metab Disord       Date:  2019-04-09

6.  Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment.

Authors:  Neal J Weinreb; Jack Goldblatt; Jacobo Villalobos; Joel Charrow; J Alexander Cole; Marcelo Kerstenetzky; Stephan vom Dahl; Carla Hollak
Journal:  J Inherit Metab Dis       Date:  2012-09-14       Impact factor: 4.982

Review 7.  Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.

Authors:  Johannes M F G Aerts; Wouter W Kallemeijn; Wouter Wegdam; Maria Joao Ferraz; Marielle J van Breemen; Nick Dekker; Gertjan Kramer; Ben J Poorthuis; Johanna E M Groener; Josanne Cox-Brinkman; Saskia M Rombach; Carla E M Hollak; Gabor E Linthorst; Martin D Witte; Henrik Gold; Gijs A van der Marel; Herman S Overkleeft; Rolf G Boot
Journal:  J Inherit Metab Dis       Date:  2011-03-29       Impact factor: 4.982

8.  Gaucher's disease.

Authors:  Vijay Bohra; Velu Nair
Journal:  Indian J Endocrinol Metab       Date:  2011-07

9.  Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Authors:  Deborah Elstein; Ari Zimran
Journal:  Biologics       Date:  2009-09-15

10.  Cost-effectiveness of enzyme replacement therapy for type 1 Gaucher disease.

Authors:  Laura van Dussen; Marieke Biegstraaten; Carla E M Hollak; Marcel G W Dijkgraaf
Journal:  Orphanet J Rare Dis       Date:  2014-04-14       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.